STAT+: Practice-changing results reported for Revolution Medicines pancreatic cancer drug

STAT PlusBiotech Practice-changing results reported for Revolution Medicines pancreatic cancer drug Daraxonrasib nearly doubled survival time compared to standard chemotherapy Manage alerts for this article Email this article Share this article By Adam FeuersteinMay 31, 2026 Senior Writer, Biotech Adam Feuerstein[email protected]Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54. CHICAGO — Rachna Shroff, a physician and pancreatic cancer expert, was seeing patients at the University of Arizona Cancer Center in April when she heard the striking clinical results about an experimental pill called daraxonrasib. Patients taking the targeted drug lived nearly twice as long as patients offered standard chemotherapy — an outcome never seen before in the pancreatic cancer field. “Having treated pancreatic cancer for 16 years, I actually started crying in the clinic,” Shroff said at a media briefing. “This is such an incredibly impactful study for our patients.”Advertisement On Sunday, detailed results from the daraxonrasib clinical trial conducted by the drug’s maker, the biotech company Revolution Medicines, were presented here at the plenary session of the annual meeting of the American Society of Clinical Oncology. The study was published simultaneously in the New England Journal of Medicine. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+. Already have an account? Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%! Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+. Subscribe Log In ASCO, biotechnology, Cancer, drug development, FDA, Pharmaceuticals, STAT+ Submit a correction requestReprints Adam Feuerstein Senior Writer, Biotech Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54. Newsletter Your morning rundown of the science, politics, and money driving biotech today Recommended Pharma May 31, 2026 Ultra-low doses could bring costly cancer treatments to more patients in poorer countries Biotech May 31, 2026 STAT Plus: Akeso and Summit’s ivonescimab extends survival in squamous cell lung cancer Advertisement Biotech May 31, 2026 STAT Plus: For prostate cancer patients set on surgery, new hormone regimen may improve outcomes, study finds Biotech May 30, 2026 STAT Plus: BioNTech and Pfizer tout bispecifics data at ASCO, and Pazdur sees silver lining at FDA Biotech May 30, 2026 STAT Plus: China competition, ‘destruction’ at FDA give agency chance to restructure, Rick Pazdur says Subscriber Picks